Microbot Medical has today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a third patent application covering the Company’s LIBERTY® Robotic System. The Company has secured all three U.S. patents during 2021. Globally, the Company now has 47 patents issued/allowed and 26 pending patent applications and is continuously submitting applications to protect its Intellectual Property.
“2021 has been an extremely successful year for our LIBERTY Robotic System – key patents and development progress leading to the recently announced design freeze – so we remain bullish on our future prospects and maintaining the positive momentum,” commented Harel Gadot, CEO, President and Chairman. “The IP and R&D teams are accomplishing meaningful milestones, which gives us greater confidence that we will continue to perform at a high level and execute the clinical and operating objectives we have planned throughout 2022.”
The allowed claims provide protection for embodiments of LIBERTY as a compact robotic device for driving movement of two or more elongate surgical tools, the device having motors and tool actuation assemblies encased within the same device housing.
Source: Microbot Medical.